This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene-sponsored or Celgene alliance partner-sponsored study.

This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory).

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced colorectal cancer patients.

In Parts A and B, approximately 150 evaluable adult advanced colorectal cancer patients with measurable disease who have radiographically progressed during or following 1 line of systemic treatment will be enrolled in the study.

This study is comparing the efficacy of the study drug RO7198457 versus “watchful waiting” in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

The purpose of this study is to test the efficacy of the combination of the study drugs tazemetostat with mosunetuzumab and see what effects it has on untreated follicular lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

This is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.

This clinical trial is for men and women with Clonal Cytopenia of Undetermined Significance (CCUS).

The purpose of this research is to test the benefit and safety of Canakinumab. Canakinumab is experimental, which means that they are being tested and are not yet approved by the United States Food and Drug Administration (FDA).

This clinical trial is for men and women with early-stage esophageal cancer (EC) or gastroesophageal junction cancer (GEJC) who are currently receiving adjuvant nivolumab prior to and independently of participation in the study.

The purpose of this study is to learn more about patients with EC or GEJC who have started with nivolumab treatment and about the use and the effects of nivolumab in clinical practice. For this reason, BMS is conducting this study to collect additional information about:

This clinical trial is for men and women who have myeloid disease, a disease caused by blood cells that are not working properly.
   

The purpose of this study is to help us learn how best to support young women making decisions about breast cancer surgery.

Over the course of this study, a web-based decision support tool (“CONSYDER”) designed for women between the ages of 18-44 who are newly diagnosed with breast cancer and making decisions about breast cancer surgery, will begin to be offered as standard of care at each study site. Because sites will be provided access to CONSYDER at different times, some study participants will have access to the tool while others will not.